Evidence map›Paper›PMID 42496766›Full record

SynthesisJournal of the Egyptian National Cancer Institute2026

Clinical efficacy and safety outcomes of anlotinib therapy in sarcoma: a systematic review and meta-analysis.

Hasan Matar, Ahmad Melhem, Abdallah Shawwa, Taleen Yousef, Mohammad Alananbeh, Enad Alsalim, Eman Al-Refai, Malaak Abuhwaij, Dina Elayan

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hasan MatarJordan University of Science and Technology, Irbid, Jordan. hasanmatar9f@gmail.com.
Ahmad MelhemJordan University of Science and Technology, Irbid, Jordan.
Abdallah ShawwaUniversity of Jordan, Amman, Jordan.
Taleen YousefJordan University of Science and Technology, Irbid, Jordan.
Mohammad AlananbehJordan University of Science and Technology, Irbid, Jordan.
Enad AlsalimJordan University of Science and Technology, Irbid, Jordan.
Eman Al-RefaiYarmouk University, Irbid, Jordan.
Malaak AbuhwaijJordan University of Science and Technology, Irbid, Jordan.
Dina ElayanJordan University of Science and Technology, Irbid, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSarcomas are rare, aggressive and unpredictable tumors that arise from mesenchymal tissues. Despite treatment, outcomes for advanced or metastatic cases remain poor. Anlotinib is a new oral tyrosine kinase inhibitor that blocks multiple angiogenic pathways and has shown encouraging results in solid tumors. This review aims to summarize and clarify the current evidence on anlotinib's role in treating sarcoma.

methodsA systematic search across five major databases up to February 2025 identified clinical studies that evaluate anlotinib in sarcoma patients. Eligible studies included randomized controlled trials and observational studies evaluating anlotinib in advanced or metastatic sarcoma. Pooled estimates for median progression-free survival (mPFS) and overall survival (mOS) were calculated using random-effects models.

resultsTwenty-one studies involving 1,230 patients were included. The pooled mPFS was 6.7 months and the mOS was 19.3 months. Results varied widely due to differences in sarcoma subtype, disease stage, and prior therapies, yet most studies showed meaningful tumor control and manageable toxicity.

conclusionsAnlotinib appears to be a promising therapy for refractory or metastatic sarcomas. It offers modest yet real improvements in survival and quality of life. Larger, multicenter and biomarker-guided studies are needed to define which patients benefit most and how this drug can be best integrated into future treatment strategies.

Indexed as

Antineoplastic AgentsIndolesProtein Kinase InhibitorsQuinolinesSarcomaHumansQuality of LifeTreatment OutcomeanlotinibAntineoplastic AgentsIndolesProtein Kinase InhibitorsQuinolinesAnlotinibMeta-analysisOverall survivalProgression-free survivalSarcomaTyrosine kinase inhibitor

Identifiers

PMID42496766
PMCPMC13400519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.